RE:RE:RE:Endpoints on Merck kGAaNovember 21, 2022 - MilliporeSigma, the US and Canadian life science division of Merck KGaA, is plunking down almost $300 million to boost biosafety testing in the US.
The company said it will invest $286 million to bulk up biosafety testing at its manufacturing site in Rockville, MD. The new, 250,000-square-foot facility expansion will extend its capacity for biosafety testing, analytical development, viral clearance suites and services for cell bank manufacturing.
The move comes on the heels of several other Merck KGaA and MilliporeSigma investments in manufacturing sites this year both in the US and Europe. In the summer, the MilliporeSigma production facility in Verona, WI, near the state capitol of Madison, opened a $65 million, 70,000-square-foot new expansion on an existing site to produce highly potent APIs.
https://endpts.com/merck-kgaas-milliporesigma-invests-286m-to-build-out-biosafety-testing/